1Yang G C,Livolsi V A,Baloch Z W.Thyroid microcarcinoma:fine-needle aspiration diagnosis and histologic follow-up[J].Int Surgathol,2002,10:133-139.
2Marcocci C,Pacini F,Elisei R,et al.Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma[J].Surgery,1989,106(6):960-966.
1Kebebew E, Peng M, Reiff E, et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine negative differentiated thyroid cancer. Surgery, 2006, 140 (6) : 960-966.
2Cohen EE, Vokes EE, Rosen LS, et al. A phase II study of axitinib (AG-013736[AG]) in patients with advanced thyroid cancers [abstract]. J Clin Oncol, 2007, 25 (18S) : 6008.
3Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64 (19) : 7099-7109.
44. Gupta V, Puttaswamy K, Lassoued W, et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma. J Clin Oncol [abstract], 2007, 25 (18S) : 6019.
5Sherman SI, Schlumberger M J, Droz J, et al. Initial results from a phase II trial ofmotesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC) [abstract]. J Clin Oncol, 2007, 25 (18S) : 6017.
6WakelingAE, Guy SP, WoodbumJR, etal. ZD1839 (Iressa) : an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res, 2002, 62 (20) : 5749-5754.
7Nobuhara Y, Onoda N, Yamashita Y, et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer, 2005, 92 (6) : 1110-1116.
8Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid, 2008, 18 (3) : 317-323.
9Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib in metastatic hereditary medullary thyroid cancer.. Follow-up results of an openlabel phase II trial [abstract]. J Clin Oncol, 2007, 25 (18S): 6018.
10Chan P, Yau T, Epstein R, et al. Treatment outcomes in anaplastic thyroid carcinoma from 1966-2006: Failure of overall survival enhancement despite four decades of progression in surgery, radiotherapy and chemoradiation [abstract]. J Clin Oncol, 2007, 25 (18S) : 16537.
